T-siHER2-NP™
HER2+ Breast Cancer
Key Facts
About Pdx Pharmaceuticals
PDX Pharmaceuticals is a private, preclinical-stage biotech focused on developing novel nanotherapeutics to overcome resistance and trigger immune responses in cancer. Its core asset is the versatile Pdx-NP™ platform, capable of systemic or intratumoral delivery of multiple payloads, enabling combination therapies aimed at difficult-to-treat solid tumors. The company has raised approximately $13.5 million to date, predominantly from non-dilutive government grants, and is preparing for clinical trials of its lead candidates, ARAC-02 and AIRISE-02, targeted for 2025. With a strong academic foundation, over 60 publications, and an extensive IP portfolio, PDX is positioning itself at the intersection of nanotechnology, AI-guided discovery, and immuno-oncology.
View full company profileTherapeutic Areas
Other HER2+ Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| PYTX-004 | Papyrus Therapeutics | Preclinical |
| Pyrotinib (SHR-1258) | Jiangsu Hengrui Medicine | Approved |
| Biosimilar to Trastuzumab | Shenzhen Salubris Pharmaceuticals | Phase III |
| Phesgo® (with Roche) | Halozyme Therapeutics | Approved |
| Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09) | ALX Oncology | Phase 1 |